Table 1.
Demographic and clinical characteristics of studies included in the meta-analysis.
| Author | Year | Location | Study design | Patients (female%) | Age(mean) | T2DM duration(year) | Complication | HbA1c(%) | Follow-up (year) | Interventions | Control measure | Dose(mg/d) | Sample size(Interventions/control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zinman (8) | 2016 | United States, Argentina, Australia, Belgium, etc. 615 centers of 40 countries | RCT | 2,036 (29%) |
63.1 | >10 | Myocardial infarction, coronary artery disease, coronary revascularization coronary artery | 7.0–10 | 3.1 | empagliflozin | placebo | 10/25 | 7,020 (4,687/2,333) |
| Radholm (9) | 2018 | United States, Argentina, Australia, Belgium, etc. 313 centers of 26 countries | RCT | 3,631 (35.8%) |
63.3 | 13.5 | Hypertension, atrial fibrillation | 7.0–10.5 | 3.6 | canagliflozin | placebo | 100/300 | 10,142 (5,795/4,347) |
| McMurray (10) | 2019 | UK., United States, Denmark, Germany, etc. 417 centers of 19 countries | RCT | 1,109 (23.4%) |
66.4 | — | Ischemic, nonischemic, atrial fibrillation, | >6.5 | 1.5 | dapagliflozin | placebo | 10 | 4,744 (2,373/2,371) |
| Cannon (11) | 2020 | United States | RCT | 2,471 (30%) | 64.4 | 12.9 | Coronary artery disease, heart failure, myocardial infarction, coronary revascularization | 7.0–10.5 | 3.5 | Ertugliflozin | placebo | 5/15 | 8,238(5,499/2,747) |
| Wiviott (17) | 2019 | United States, Argentina, Australia, Belgium, etc. 804 centers of 33 countries | RCT | 6,422 (37.4%) |
64 | 11 | Coronary artery disease, peripheral artery disease | 6.5–12 | 4.2 | dapagliflozin | placebo | 10 | 17,160 (8,582/8,578) |
| Kosiborod (18) | 2017 | United States | RCT | 119 (37.2%) |
64.3 | 13.5–14 | Coronary artery disease, atrial fibrillation | 7.3–9.1 | 1 | dapagliflozin | placebo | 10 | 320 (171/149) |
| Isreb (19) | 2019 | United States, Argentina, Australia, Brazil, etc. 593 centers of 34 countries. | RCT | 1,492 (33.9%) |
63 | — | Hypertension, cardiovascular disease | 6.5–10.5 | 2.62 | canagliflozin | placebo | 100 | 4,401 (2,202/2,199) |
| Packer (20) | 2020 | United States, Argentina, Australia, Belgium, etc. 520 centers of 20 countries. | RCT | 893 (23.9%) |
66.9 | — | Heart failure, atrial fibrillation, hypertension | — | 1.33 | empagliflozin | placebo | 10 | 3,730 (1,863/1,867) |